



US012390593B2

(12) **United States Patent**
Ekman et al.

(10) **Patent No.:** **US 12,390,593 B2**

(45) **Date of Patent:** ***Aug. 19, 2025**

(54) **AUTO-INJECTOR**

(71) Applicant: **Sanofi-Aventis Deutschland GMBH**,
Frankfurt am Main (DE)

(72) Inventors: **Matthew Ekman**, Cheshire (GB);
Timothy Donald Barrow-Williams, St.
Albans Herts (GB); **Yannick**
Hourmand, Haslingfield (GB)

(73) Assignee: **Sanofi-Aventis Deutschland GMBH**,
Frankfurt am Main (DE)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **18/678,521**

(22) Filed: **May 30, 2024**

(65) **Prior Publication Data**

US 2024/0307621 A1 Sep. 19, 2024

Related U.S. Application Data

(63) Continuation of application No. 17/453,601, filed on
Nov. 4, 2021, which is a continuation of application
(Continued)

(30) **Foreign Application Priority Data**

Feb. 18, 2010 (EP) 10153999

(51) **Int. Cl.**

A61M 5/20 (2006.01)

A61M 5/32 (2006.01)

(52) **U.S. Cl.**

CPC **A61M 5/2033** (2013.01); **A61M 5/3202**
(2013.01); **A61M 5/3232** (2013.01);
(Continued)

(58) **Field of Classification Search**

CPC **A61M 5/2033**; **A61M 5/3202**; **A61M**
5/3232; **A61M 5/3204**; **A61M 5/326**;
A61M 2005/206; **A61M 2005/2073**

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,712,301 A 1/1973 Sarnoff
4,394,863 A 7/1983 Bartner
(Continued)

FOREIGN PATENT DOCUMENTS

CH 705345 2/2013
CH 705992 6/2013
(Continued)

OTHER PUBLICATIONS

U.S. Appl. No. 18/678,364, filed May 30, 2024, Ekman et al.*
(Continued)


Primary Examiner — Quynh-Nhu H. Vu

(74) *Attorney, Agent, or Firm* — Fish & Richardson P.C.

(57) **ABSTRACT**

An auto-injector for administering a dose of a liquid medi-
cament includes an elongate housing arranged to contain a
syringe with a hollow needle and a stopper for sealing the
syringe and displacing the medicament, the housing having
a distal end and a proximal end with an orifice intended to
be applied against an injection site. The syringe is slidably
arranged with respect to the housing. A spring capable of,
upon activation: pushing the needle from a covered position
inside the housing into an advanced position through the
orifice and past the proximal end (P), operating the syringe
to supply the dose of medicament (M), and retracting the
syringe with the needle into the covered position. After
delivering the medicament, an activator arranged to lock the

(Continued)



spring in a pressurized state prior to manual operation and capable of, upon manual operation, releasing the spring for injection.

30 Claims, 4 Drawing Sheets

Related U.S. Application Data

No. 16/276,366, filed on Feb. 14, 2019, now Pat. No. 11,197,958, which is a continuation of application No. 14/995,964, filed on Jan. 14, 2016, now Pat. No. 10,232,116, which is a continuation of application No. 13/579,435, filed as application No. PCT/EP2011/052301 on Feb. 16, 2011, now Pat. No. 9,248,245.

(60) Provisional application No. 61/412,086, filed on Nov. 10, 2010.

(52) U.S. Cl.

CPC *A61M 2005/206* (2013.01); *A61M 2005/2073* (2013.01); *A61M 5/3204* (2013.01); *A61M 5/326* (2013.01)

(56) References Cited

U.S. PATENT DOCUMENTS

4,976,701	A	12/1990	Ejlertsen et al.
5,137,516	A	8/1992	Rand et al.
5,267,963	A	12/1993	Bachynsky
5,300,030	A	4/1994	Crossman et al.
5,358,489	A	10/1994	Wyrick
5,643,214	A	7/1997	Marshall et al.
5,820,602	A	10/1998	Kovelman et al.
6,004,297	A	12/1999	Steenfeldt-Jensen et al.
6,277,099	B1	8/2001	Strowe et al.
6,371,939	B2	4/2002	Bergens et al.
6,454,743	B1	9/2002	Weber
6,620,137	B2	9/2003	Kirchhofer et al.
7,097,634	B2	8/2006	Gilbert
7,195,616	B2	3/2007	Diller et al.
7,291,132	B2	11/2007	DeRuntz et al.
7,297,135	B2	11/2007	Jeffrey
7,341,575	B2	3/2008	Rice
7,597,685	B2	10/2009	Olson
7,666,164	B2	2/2010	Giambattista et al.
7,678,085	B2	3/2010	Graf
7,717,877	B2	5/2010	Lavi et al.
7,771,397	B1	8/2010	Olson
7,771,398	B2	8/2010	Knight et al.
7,811,261	B2	10/2010	Rubinstein et al.
7,901,377	B1*	3/2011	Harrison A61M 5/2033 604/157
7,918,824	B2	4/2011	Bishop et al.
7,976,494	B2	7/2011	Kohlbrener et al.
7,976,499	B2	7/2011	Grunhut et al.
7,976,514	B2	7/2011	Abry et al.
7,988,675	B2	8/2011	Gillespie et al.
8,038,649	B2	10/2011	Kronstedt
8,048,037	B2	11/2011	Kohlbrener et al.
8,062,255	B2	11/2011	Brunnberg et al.
8,083,711	B2	12/2011	Enggaard
8,277,412	B2	10/2012	Kronstedt
8,277,414	B2	10/2012	Barrow-Williams et al.
8,323,238	B2	12/2012	Cronenberg et al.
8,357,125	B2	1/2013	Grunhut et al.
8,361,025	B2	1/2013	Lawlis et al.
8,366,680	B2	2/2013	Raab
8,376,993	B2	2/2013	Cox et al.
8,376,997	B2	2/2013	Hogdahl et al.
8,398,594	B2	3/2013	Streit et al.

8,403,883	B2	3/2013	Fayyaz et al.
8,409,138	B2	4/2013	James et al.
8,409,141	B2	4/2013	Johnsen et al.
8,409,148	B2	4/2013	Fiechter et al.
8,414,533	B2	4/2013	Alexandersson
8,439,864	B2	5/2013	Galbraith et al.
8,491,538	B2	7/2013	Kohlbrener et al.
8,551,054	B2	10/2013	Guillermo
8,568,359	B2	10/2013	Carrel et al.
8,579,865	B2	11/2013	Wotton et al.
8,579,866	B2	11/2013	Morgan et al.
8,617,109	B2	12/2013	Kronstedt et al.
8,617,124	B2	12/2013	Wieselblad et al.
8,632,507	B2	1/2014	Bartha
8,684,969	B2	4/2014	Moller et al.
8,708,973	B2	4/2014	Holmqvist
8,734,394	B2	5/2014	Adams et al.
8,734,402	B2	5/2014	Sharp et al.
8,758,292	B2	6/2014	Tschirren et al.
8,808,250	B2	8/2014	Ekman et al.
8,808,251	B2	8/2014	Raab et al.
8,821,451	B2	9/2014	Daniel
8,834,431	B2	9/2014	Kohlbrener et al.
8,840,591	B2	9/2014	Raab et al.
8,882,723	B2	11/2014	Smith et al.
8,911,410	B2	12/2014	Ekman et al.
8,911,411	B2	12/2014	Nielsen
8,939,934	B2	1/2015	Brereton et al.
8,945,063	B2	2/2015	Wotton et al.
8,956,331	B2	2/2015	Johnsen et al.
8,961,473	B2	2/2015	Heald
8,968,256	B2	3/2015	Raab
8,968,258	B2	3/2015	Nzike et al.
8,992,484	B2	3/2015	Radmer et al.
8,992,487	B2	3/2015	Eich et al.
9,005,160	B2	4/2015	Karlsson et al.
9,011,386	B2	4/2015	Kronstedt et al.
9,011,387	B2	4/2015	Ekman et al.
9,022,991	B1	5/2015	Moeller
9,022,994	B2	5/2015	Moser et al.
9,044,548	B2	6/2015	Miller et al.
9,044,553	B2	6/2015	James et al.
9,057,369	B2	6/2015	Kohlbrener et al.
9,061,104	B2	6/2015	Daniel
9,067,024	B2	6/2015	Roberts et al.
9,089,652	B2	7/2015	Nzike et al.
9,108,002	B2	8/2015	Markussen
9,125,988	B2	9/2015	Karlsson
9,132,235	B2	9/2015	Holmqvist
9,199,038	B2	12/2015	Daniel
9,205,199	B2	12/2015	Kemp et al.
9,216,256	B2	12/2015	Olson et al.
9,233,213	B2	1/2016	Olson et al.
9,233,214	B2	1/2016	Kemp et al.
9,233,215	B2	1/2016	Hourmand et al.
9,242,044	B2	1/2016	Markussen
9,272,098	B2	3/2016	Hourmand et al.
9,283,326	B2	3/2016	Kemp et al.
9,283,327	B2	3/2016	Hourmand et al.
9,283,328	B2	3/2016	Dasbach
9,308,327	B2	4/2016	Marshall et al.
9,333,304	B2	5/2016	Brereton et al.
9,339,607	B2	5/2016	Langley et al.
9,352,088	B2	5/2016	Ekman et al.
9,358,345	B2	6/2016	Brereton et al.
9,358,351	B2	6/2016	Ekman et al.
9,393,368	B2	7/2016	Nzike et al.
9,402,957	B2	8/2016	Adams et al.
9,408,976	B2	8/2016	Olson
9,408,977	B2	8/2016	Butler et al.
9,408,979	B2	8/2016	Veasey et al.
9,415,165	B2	8/2016	Cowe
9,421,336	B2	8/2016	Ekman et al.
9,427,525	B2	8/2016	Barrow-Williams et al.
9,446,196	B2	9/2016	Hourmand et al.
9,446,201	B2	9/2016	Holmqvist
9,457,149	B2	10/2016	Kemp et al.
9,457,152	B2	10/2016	Raab et al.
9,492,622	B2	11/2016	Brereton et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

9,649,441	B2	5/2017	Barrow-Williams et al.
9,662,452	B2	5/2017	Daniel
9,675,758	B2	6/2017	Johnston
9,867,940	B2	1/2018	Holmqvist et al.
9,872,961	B2	1/2018	Fourt et al.
10,118,001	B2	11/2018	Fourt et al.
10,314,981	B2	6/2019	Sampson et al.
10,350,356	B2	7/2019	Hirschel et al.
10,350,362	B2	7/2019	Dennis, Jr. et al.
10,363,377	B2	7/2019	Atterbury et al.
10,420,898	B2	9/2019	Daniel
10,569,019	B2	2/2020	Hirschel et al.
10,799,647	B2	10/2020	Hostettler et al.
10,881,799	B2	1/2021	Hirschel et al.
11,298,462	B2	4/2022	Atterbury et al.
11,383,044	B2	7/2022	Tschirren et al.
11,452,821	B2	9/2022	Lafever et al.
11,484,653	B1	11/2022	Ekman et al.
11,730,888	B2	8/2023	Ekman et al.
12,083,319	B2	9/2024	Ekman et al.
12,090,302	B2	9/2024	Ekman et al.
12,090,303	B2	9/2024	Ekman et al.
2002/0007154	A1	1/2002	Hansen et al.
2002/0095120	A1	7/2002	Larsen et al.
2003/0105430	A1	6/2003	Lavi et al.
2004/0024367	A1	2/2004	Gilbert
2004/0039336	A1	2/2004	Amark et al.
2005/0101919	A1	5/2005	Brunnberg et al.
2005/0165360	A1	7/2005	Stamp
2005/0203466	A1	9/2005	Hommann et al.
2005/0222539	A1	10/2005	Gonzales et al.
2006/0129089	A1	6/2006	Stamp
2006/0153693	A1	7/2006	Fiechter et al.
2006/0184117	A1	8/2006	Knight et al.
2006/0287630	A1	12/2006	Hommann
2007/0027430	A1	2/2007	Hommann
2007/0112310	A1	5/2007	Lavi et al.
2007/0135767	A1	6/2007	Gillespie et al.
2007/0173770	A1	7/2007	Stamp
2008/0147006	A1	6/2008	Brunnberg et al.
2008/0262427	A1	10/2008	Hommann
2008/0269692	A1	10/2008	James et al.
2009/0012471	A1	1/2009	Harrison
2009/0054849	A1	2/2009	Burnell et al.
2009/0264828	A1	10/2009	Dette et al.
2010/0016793	A1	1/2010	Jennings et al.
2010/0016795	A1	1/2010	McLoughlin
2010/0049125	A1*	2/2010	James A61M 5/2033 604/110
2010/0094214	A1	4/2010	Abry et al.
2010/0130930	A1	5/2010	Stamp et al.
2010/0152655	A1	6/2010	Stamp
2010/0185178	A1	7/2010	Sharp et al.
2011/0054411	A1	3/2011	Dowds et al.
2011/0178500	A1	7/2011	Shang et al.
2011/0282278	A1	11/2011	Stamp et al.
2011/0319864	A1	12/2011	Beller et al.
2012/0010575	A1	1/2012	Jones et al.
2012/0041387	A1	2/2012	Bruggemann et al.
2012/0053528	A1	3/2012	Bollenbach et al.
2012/0172817	A1	7/2012	Bruggemann et al.
2013/0035647	A1	2/2013	Veasey et al.
2013/0041328	A1	2/2013	Daniel
2013/0123710	A1	5/2013	Ekman et al.
2013/0261556	A1	10/2013	Jones et al.
2013/0274662	A1	10/2013	Hourmand et al.
2013/0274677	A1	10/2013	Ekman et al.
2013/0289525	A1	10/2013	Kemp et al.
2013/0345643	A1	12/2013	Hourmand et al.
2015/0273157	A1	10/2015	Kohlbrener et al.
2016/0089498	A1	3/2016	Daniel
2018/0064875	A1	3/2018	Holmqvist
2019/0374717	A1	12/2019	Swanson et al.
2020/0139047	A1	5/2020	Hirschel et al.
2021/0154407	A1	5/2021	Hirschel et al.

2022/0211946	A1	7/2022	Ekman et al.
2022/0323678	A1	10/2022	Ekman et al.
2023/0022361	A1	1/2023	Heiniger et al.
2023/0181827	A1	6/2023	Ekman et al.
2024/0197997	A1	6/2024	Ekman et al.
2024/0197998	A1	6/2024	Ekman et al.
2024/0238520	A1	7/2024	Ekman et al.
2024/0307622	A1	9/2024	Ekman et al.
2024/0316269	A1	9/2024	Ekman et al.
2024/0316270	A1	9/2024	Ekman et al.
2024/0316271	A1	9/2024	Ekman et al.
2024/0316272	A1	9/2024	Ekman et al.
2024/0316273	A1	9/2024	Ekman et al.
2024/0316274	A1	9/2024	Ekman et al.
2024/0316275	A1	9/2024	Ekman et al.
2025/0152819	A1	5/2025	Ekman et al.
2025/0152820	A1	5/2025	Ekman et al.
2025/0152821	A1	5/2025	Ekman et al.
2025/0152822	A1	5/2025	Ekman et al.
2025/0152823	A1	5/2025	Ekman et al.

FOREIGN PATENT DOCUMENTS

DE	19819409	11/1999	
DE	102005038933	2/2007	
DE	202007000578	3/2007	
DE	102005052502	5/2007	
EP	0666084	8/1995	
EP	0824923	2/1998	
EP	0991441	12/2003	
EP	2399634	12/2011	
EP	2468334	6/2012	
EP	2468335	6/2012	
EP	2742962	6/2014	
EP	3650064	5/2020	
EP	3381490	9/2020	
EP	3184138	4/2023	
FR	2654938	5/1991	
GB	2438592	12/2007	
GB	2438592	A *	12/2007
JP	H08-502180	3/1996	
JP	2002-528182	9/2002	
JP	2007-500530	1/2007	
WO	WO 1994/004103	3/1994	
WO	WO 1995/035126	A1	12/1995
WO	WO 1999/053979		10/1999
WO	WO 2000/024441		5/2000
WO	WO 2002/047746		6/2002
WO	WO 2003/062672		7/2003
WO	WO 2003/097133	A1	11/2003
WO	WO 2005/009515		2/2005
WO	WO 2005/070481		8/2005
WO	WO 2005/097238		10/2005
WO	WO 2005/115507		12/2005
WO	WO 2006/057604		6/2006
WO	WO 2006/079064		7/2006
WO	WO 2007/083115		7/2007
WO	WO 2007/099044		9/2007
WO	WO 2007/129324		11/2007
WO	WO 2008/059385		5/2008
WO	WO 2008/116688		10/2008
WO	WO 2008/155377		12/2008
WO	WO 2009/019440		2/2009
WO	WO 2009/040601		4/2009
WO	WO 2009/040603		4/2009
WO	WO 2009/040607		4/2009
WO	WO 2009/040672		4/2009
WO	WO 2009/062508		5/2009
WO	WO 2009/081103		7/2009
WO	WO 2010/007395		1/2010
WO	WO 2010/063707		6/2010
WO	WO 2010/136077		12/2010
WO	WO 2011/012903		2/2011
WO	WO 2011/043714		4/2011
WO	WO 2011/075101		6/2011
WO	WO 2011/109205		9/2011
WO	WO 2011/111006		9/2011
WO	WO 2011/117592		9/2011
WO	WO 2011/123024		10/2011

(56)

References Cited



FOREIGN PATENT DOCUMENTS




WO	WO 2011/126439	10/2011
WO	WO 2012/045350	4/2012
WO	WO 2012/085024	6/2012
WO	WO 2019/074788	4/2019
WO	WO 2020/190529	9/2020
WO	WO 2021/008839	1/2021
WO	WO 2021/160540	8/2021
WO	WO 2021/197804	10/2021
WO	WO 2022/069617	4/2022
WO	WO 2022/184388	9/2022



OTHER PUBLICATIONS

International Preliminary Report on Patentability in Application No.
PCT/EP2011/052301, dated Aug. 21, 2012, 6 pages.
International Search Report and Written Opinion in Application No.
PCT/EP2011/052301, dated May 26, 2011, 9 pages.

* cited by examiner





254




FIG 3




FIG 4

FIG 6

1

AUTO-INJECTOR

CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 17/453,601, filed Nov. 4, 2021, which is a continuation of U.S. patent application Ser. No. 16/276,366, filed Feb. 14, 2019, now U.S. Pat. No. 11,197,958, which is a continuation of U.S. patent application Ser. No. 14/995,964, filed Jan. 14, 2016, now U.S. Pat. No. 10,232,116, which is a continuation of U.S. patent application Ser. No. 13/579,435, filed Feb. 25, 2013, now U.S. Pat. No. 9,248,245, which is a 35 U.S.C. 371 National Application of PCT/EP2011/052301, filed Feb. 16, 2011, and claims priority to European Patent Application No. 10153999.7, filed Feb. 18, 2010 and U.S. Patent Application No. 61/412,086, filed Nov. 10, 2010, the entire contents of which are incorporated entirely herein by reference.

TECHNICAL FIELD

The invention relates to an auto-injector for administering a dose of a liquid medicament according to the preamble of claim 1.

BACKGROUND OF THE INVENTION

Administering an injection is a process which presents a number of risks and challenges for users and healthcare professionals, both mental and physical.

Injection devices (i.e. devices capable of delivering medicaments from a medication container) typically fall into two categories—manual devices and auto-injectors.

In a manual device—the user must provide the mechanical energy to drive the fluid through the needle. This is typically done by some form of button/plunger that has to be continuously pressed by the user during the injection. There are numerous disadvantages to the user from this approach. If the user stops pressing the button/plunger then the injection will also stop. This means that the user can deliver an underdose if the device is not used properly (i.e. the plunger is not fully pressed to its end position). Injection forces may be too high for the user, in particular if the patient is elderly or has dexterity problems.

The extension of the button/plunger may be too great. Thus it can be inconvenient for the user to reach a fully extended button. The combination of injection force and button extension can cause trembling/shaking of the hand which in turn increases discomfort as the inserted needle moves.

Auto-injector devices aim to make self-administration of injected therapies easier for patients. Current therapies delivered by means of self-administered injections include drugs for diabetes (both insulin and newer GLP-1 class drugs), migraine, hormone therapies, anticoagulants etc.

Auto-injectors are devices which completely or partially replace activities involved in parenteral drug delivery from standard syringes. These activities may include removal of a protective syringe cap, insertion of a needle into a patient's skin, injection of the medicament, removal of the needle, shielding of the needle and preventing reuse of the device. This overcomes many of the disadvantages of manual devices. Injection forces/button extension, hand-shaking and the likelihood of delivering an incomplete dose are reduced. Triggering may be performed by numerous means, for

2

example a trigger button or the action of the needle reaching its injection depth. In some devices the energy to deliver the fluid is provided by a spring.

US 2002/0095120 A1 discloses an automatic injection device which automatically injects a pre-measured quantity of fluid medicine when a tension spring is released. The tension spring moves an ampoule and the injection needle from a storage position to a deployed position when it is released. The content of the ampoule is thereafter expelled by the tension spring forcing a piston forward inside the ampoule. After the fluid medicine has been injected, torsion stored in the tension spring is released and the injection needle is automatically retracted back to its original storage position.

US 2007/0112310 A1 discloses an injector being automatic in that the needle is inserted into the injection site (e.g., a patient's skin) with user or caregiver assistance, the delivery is automatically initiated upon needle insertion, and the needle is retracted automatically after the end of delivery. Preferably the needle is not seen by the user prior to, during or after injection. Prior to and after injection, the needle is hidden in the device so as to avoid any potential injury or health risk to the user or health care provider. The injector includes a housing and a shield arranged to slide relative to the housing and a driver moving during drug delivery. The housing and shield form a cartridge enclosure. The cartridge is shielded and locked after delivery is completed. A needle-locking mechanism can be used in any number of pen-like injectors or safety needles.

U.S. Pat. No. 5,267,963 discloses an automatic injection device which, upon activation by the user, automatically extends a syringe with needle, delivers medication through the needle, and retracts the needle, thus keeping the needle hidden from view. All motions are achieved by means of a tension spring and a cam profile.

WO 2009/081103 A1 discloses an auto-injector for a syringe that is suitable for use in the injected delivery of drug to a patient. The auto-injector comprises a housing defining a housing cavity arranged for receipt of a syringe; and a needle delivery aperture through which a needle tip of the syringe protrudes during dispensing of the liquid drug formulation. The auto-injector further comprises a barrel coupling element that couples to the barrel of the syringe and is movable in tandem therewith; a syringe advancer for moving the syringe and barrel coupling element in tandem therewith from a rest position, in which the hollow needle, is within the housing to a use position, in which the needle tip protrudes through the needle delivery aperture; a syringe actuator for actuating the syringe by plunging said plunger within the barrel of the syringe to dispense the liquid drug formulation; a syringe retractor for retracting the syringe and barrel coupling element in tandem therewith from the use position to a retract position, in which the hollow needle is within the housing; and a syringe lock for locking the barrel coupling element and syringe coupled thereto in the retract position.

WO 2008/155377 discloses an inserter for an infusion set comprising an insertion needle and a spring unit assuring automatic insertion and automatic retraction of the insertion needle. The inserter for a medical device comprises—a housing, —a first body which is movable relative to the housing and comprising penetrating means pointing in the direction of insertion, —a second body which is also movable relative to the housing and—driving means which move respectively the first body and the second body relative to the housing wherein the driving means moves the first body

3

in the direction of insertion and moves the second body in a direction different from the insertion direction.

DE 10 2005 038 933 A1 discloses an inserter for an infusion set comprising an insertion needle and a spring unit assuring automatic insertion and automatic retraction of the insertion needle. The inserter for a medical device comprises—a housing, —a first body which is movable relative to the housing and comprising penetrating means pointing in the direction of insertion, —a second body which is also movable relative to the housing and—driving means which move respectively the first body and the second body relative to the housing wherein the driving means moves the first body in the direction of insertion and moves the second body in a direction different from the insertion direction.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide an improved auto-injector.

The object is achieved by an auto-injector according to claim 1.

Preferred embodiments of the invention are given in the dependent claims.

According to the invention, an auto-injector for administering a dose of a liquid medicament comprises:

- an elongate housing arranged to contain a syringe with a hollow needle and a stopper for sealing the syringe and displacing the medicament, the housing having a distal end and a proximal end with an orifice intended to be applied against an injection site, wherein the syringe is slidably arranged with respect to the housing,

- spring means capable of, upon activation:

- pushing the needle from a covered position inside the housing into an advanced position through the orifice and past the proximal end,

- operating the syringe to supply the dose of medicament, and

- retracting the syringe with the needle into the covered position after delivering the medicament,

- activating means arranged to lock the spring means in a pressurized state prior to manual operation and capable of, upon manual operation, releasing the spring means for injection.

In the context of this patent application the term proximal refers to the direction pointing towards the patient during an injection while the term distal refers to the opposite direction pointing away from the patient.

According to the invention the spring means is a single compression spring arranged to be grounded at a distal end in the housing for advancing the needle and for injecting the dose of medicament. The force of the compression spring is forwarded to the needle and/or the syringe via a plunger. The compression spring is arranged to have its ground in the housing switched to its proximal end for retracting the syringe when the injection of the medicament is at least nearly finished.

The single compression spring is used for inserting the needle, fully emptying the syringe and retracting the syringe and needle to a safe position after injection. Thus a second spring for withdrawing the syringe and needle, which is a motion with an opposite sense compared to advancing the syringe and injecting the dose, is not required. While the distal end of the compression spring is grounded the proximal end moves the syringe forward for inserting the needle and carries on to the injection by pushing on the stopper. When the injection is at least nearly finished the compression spring bottoms out at its proximal end, resulting in the

4

proximal end being grounded in the housing. At the same time the distal end of the compression spring is released from its ground in the housing. The compression spring is now pulling the syringe in the opposite direction.

The auto-injector according to the invention has a particularly low part count compared to most conventional auto-injectors. The use of just one compression spring reduces the amount of metal needed and thus consequently reduces weight and manufacturing costs.

In a preferred embodiment of the invention a retraction sleeve is axially movable arranged in the housing. At least one latch is provided for axially fixing the retraction sleeve in a maximum proximal position. The compression spring is arranged inside the retraction sleeve with its distal end bearing against a distal end face of the retraction sleeve and with its proximal end bearing against a thrust face of a decoupling member. The decoupling member is arranged to decouple the latch when being moved in proximal direction nearly into a maximum proximal position. When decoupled the retraction sleeve is allowed to move in distal direction and retract the needle by means of the spring force which is no longer grounded at its distal end.

Preferably the plunger is arranged for pushing the syringe and/or the stopper in proximal direction. At least two resilient decoupling arms are arranged at the decoupling member. The decoupling arms exhibit inner ramped surfaces bearing against a first shoulder of the plunger in proximal direction P. The resilient decoupling arms are supportable by an inner wall of the retraction sleeve in order to prevent the decoupling arms from being flexed outward and slip past the first shoulder. In this state the plunger may be pushed in proximal direction by the decoupling member pushing against the first shoulder in order to insert the needle and inject the dose. At least one aperture is arranged in the retraction sleeve allowing the decoupling arms to be flexed outward by the first shoulder thus allowing the first shoulder to slip through the decoupling arms in proximal direction. This may happen when the injection is at least nearly finished. The decoupled plunger allows the syringe and needle to be retracted since it is no longer bearing against the decoupling member.

The syringe may be arranged for joint axial movement with a syringe holder which is slidably arranged in the retraction sleeve. The syringe holder is provided with at least two resilient syringe holder arms arranged distally, the syringe holder arms having a respective inclined surface for bearing against a second shoulder, which is arranged at the plunger proximally from the first shoulder. The syringe holder arms are supportable by an inner surface of the housing in order to prevent them from being flexed outward. Thus, when the trigger button is pressed the spring force forwarded by the plunger does not yet press against the stopper but against the syringe for forwarding it. Consequently, a so called wet injection is avoided, i.e. the liquid medicament is not leaking out of the hollow needle before the needle is inserted. A widened portion is provided in the housing for allowing the syringe holder arms to flex outwards when the syringe holder has nearly reached a maximum proximal position thus allowing the second shoulder to slip through the syringe holder arms and to switch load of the compression spring from the syringe to the stopper. This allows for defining the moment to start injecting the medicament.

A stud may be arranged at the distal end of the plunger. The retraction sleeve may have two or more resilient arms distally from the end face for holding the stud. The stud and/or the resilient arms have ramp features. Thus the

5

resilient arms may be pushed apart by the stud when the plunger is moved in proximal direction. The activating means comprise a trigger button arranged at the distal end of the auto-injector. The trigger button is axially moveable and has at least two rigid retainers for preventing the resilient arms from being flexed outward when the trigger button is in a maximum distal position. Upon pushing the trigger button in proximal direction the retainers are moved in proximal direction in a manner to allow the resilient arms to be flexed out by the stud biased by the compression spring in proximal direction. Thus the stud is allowed to slip past the resilient arms in proximal direction under load of the compression spring in order to start a needle insertion/injection/retraction cycle. The main advantages of this trigger mechanism are its simplicity, the low part count and a high reliability.

In order to reduce the risk of unintentionally triggering the auto-injector a safety button may be arranged laterally at the housing. The safety button has an interlock for preventing the trigger button from being pushed. The safety button is arranged to pull the interlock outward when operated thus allowing the trigger button to be pushed. For this purpose the safety button may be pivoted in the housing or it may be cast in one piece with the housing in a manner to be pivoted somewhere in the middle so pushing one end inwards causes the other end to be pulled outwards.

Consequently, in order to operate the trigger button the safety button has to be pushed first so the auto-injector cannot be operated unintentionally. Another advantage of the lateral safety button is that the risk of operating the auto-injector in the wrong orientation and injecting into the thumb is reduced.

In a preferred embodiment of the invention a delay box is arranged for slowing down the motion of the retraction sleeve. The latches are arranged to be disengaged by the decoupling member before the stopper has reached a maximum proximal position in the syringe. The apertures are arranged to meet the decoupling arms after the stopper has reached its maximum proximal position by means of the motion of the retraction sleeve. A gap is provided between a front face of the retraction sleeve and the syringe holder in their respective maximum proximal positions. The gap allows the retraction sleeve to travel a distance before retracting the syringe holder so the syringe holder is retracted after the decoupling arms met the apertures.

Triggering the retraction when the stopper exactly reaches the end of its travel is a problem due to tolerances when manufacturing the syringe and stopper. Due to these tolerances the position of the stopper at the end of its travel is not repeatable. Consequently, in some cases the stopper would prematurely bottom out so the retraction would not be triggered at all. In other cases the retraction would be triggered before the stopper bottomed so residual medication would remain in the syringe.

Releasing the retraction sleeve from the housing a certain amount of time or travel before the stopper bottoms out in the syringe avoids the risk of stalling the retraction by the stopper hitting the end of the syringe prematurely. The damped backward motion of the retraction sleeve due to the delay box allows the plunger and stopper to finish their forward travel so the syringe is entirely emptied. The apertures of the retraction sleeve and the decoupling arms, which are now moving in opposite directions, meet after the stopper and plunger have stopped in order to decouple the decoupling member from the plunger. Due to the gap between the front face and the syringe holder the retraction sleeve is not immediately dragging the syringe back in distal

6

direction when starting to move back. When the retraction sleeve has travelled back far enough to close the gap the stopper has already bottomed out and the plunger has been decoupled from the decoupling member. As soon as the gap is closed the syringe holder, the syringe, the hollow needle and the plunger are dragged back in distal direction.

Thus both problems are solved, reliably retracting the hollow needle to a safe position and fully emptying the syringe which is particularly desirable with expensive drugs. Emptying the syringe is also important for dosage accuracy.

The delay box may comprise a circumferential outer wall with a back collar attached to the housing and a circumferential inner wall with a front collar attached to the retraction sleeve. A volume is defined between the outer wall and inner wall, the volume sealed by the back collar and front collar and filled with a viscous fluid. At least one hole is arranged in the delay box for allowing the viscous fluid to be pushed out as the volume decreases due to motion of the retraction sleeve. This is a particularly simple and cost-efficient way to damp the backward motion of the retraction sleeve.

Usually the hollow needle is equipped with a protective needle shield for keeping the needle sterile and preventing it from being mechanically damaged. The protective needle shield is attached to the needle when the auto-injector or the syringe is assembled.

Preferably a cap is provided at the proximal end of the housing. A sheet metal clip is attached to the cap for joint axial movement and independent rotation. The sheet metal clip is arranged to extend through an orifice into the housing when the cap is attached to the housing. The sheet metal clip comprises at least two barbs snapped into a circumferential notch or behind a shoulder of the protective needle shield. This allows for automatically engaging the sheet metal clip with the protective needle shield during assembly. When the cap is removed from the housing in preparation of an injection the protective needle shield is reliably removed without exposing the user too high a risk to injure themselves.

The cap may be attachable to the housing by a screw connection. This allows for a low force removal of the protective needle shield.

The housing may have at least one viewing window for inspecting the syringe.

The auto-injector may preferably be used for subcutaneous or intra-muscular injection, particularly for delivering one of an analgetic, an anticoagulant, insulin, an insulin derivate, heparin, Lovenox, a vaccine, a growth hormone, a peptide hormone, a proteine, antibodies and complex carbohydrates.

The term "medicament", as used herein, means a pharmaceutical formulation containing at least one pharmaceutically active compound,

wherein in one embodiment the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a proteine, a polysaccharide, a vaccine, a DNA, a RNA, an antibody, an enzyme, an antibody, a hormone or an oligonucleotide, or a mixture of the above-mentioned pharmaceutically active compound,

wherein in a further embodiment the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer,

macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis, wherein in a further embodiment the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, wherein in a further embodiment the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1) or an analogue or derivative thereof, or exedin-3 or exedin-4 or an analogue or derivative of exedin-3 or exedin-4.

Insulin analogues are for example Gly(A21), Arg(B31), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.

Insulin derivatives are for example B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; B29-N-(ω -carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω -carboxyheptadecanoyl) human insulin.

Exedin-4 for example means Exedin-4(1-39), a peptide of the sequence H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂.

Exedin-4 derivatives are for example selected from the following list of compounds:

H-(Lys)4-des Pro36, des Pro37 Exedin-4(1-39)-NH₂,
H-(Lys)5-des Pro36, des Pro37 Exedin-4(1-39)-NH₂,
des Pro36 [Asp28] Exedin-4(1-39),
des Pro36 [IsoAsp28] Exedin-4(1-39),
des Pro36 [Met(O)14, Asp28] Exedin-4(1-39),
des Pro36 [Met(O)14, IsoAsp28] Exedin-4(1-39),
des Pro36 [Trp(O)25, Asp28] Exedin-4(1-39),
des Pro36 [Trp(O)25, IsoAsp28] Exedin-4(1-39),
des Pro36 [Met(O)14 Trp(O)25, Asp28] Exedin-4(1-39),
des Pro36 [Met(O)14 Trp(O)25, IsoAsp28] Exedin-4(1-39); or
des Pro36 [Asp28] Exedin-4(1-39),
des Pro36 [IsoAsp28] Exedin-4(1-39),
des Pro36 [Met(O)14, Asp28] Exedin-4(1-39),
des Pro36 [Met(O)14, IsoAsp28] Exedin-4(1-39),
des Pro36 [Trp(O)25, Asp28] Exedin-4(1-39),
des Pro36 [Trp(O)25, IsoAsp28] Exedin-4(1-39),
des Pro36 [Met(O)14 Trp(O)25, Asp28] Exedin-4(1-39),
des Pro36 [Met(O)14 Trp(O)25, IsoAsp28] Exedin-4(1-39),
wherein the group -Lys6-NH₂ may be bound to the C-terminus of the Exedin-4 derivative;
or an Exedin-4 derivative of the sequence
H-(Lys)6-des Pro36 [Asp28] Exedin-4(1-39)-Lys6-NH₂,
des Asp28 Pro36, Pro37, Pro38 Exedin-4(1-39)-NH₂,

H-(Lys)6-des Pro36, Pro38 [Asp28] Exedin-4(1-39)-NH₂,
H-Asn-(Glu)5des Pro36, Pro37, Pro38 [Asp28] Exedin-4(1-39)-NH₂,
des Pro36, Pro37, Pro38 [Asp28] Exedin-4(1-39)-(Lys)6-NH₂,
H-(Lys)6-des Pro36, Pro37, Pro38 [Asp28] Exedin-4(1-39)-(Lys)6-NH₂,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Asp28] Exedin-4(1-39)-(Lys)6-NH₂,
H-(Lys)6-des Pro36 [Trp(O)25, Asp28] Exedin-4(1-39)-Lys6-NH₂,
H-des Asp28 Pro36, Pro37, Pro38 [Trp(O)25] Exedin-4(1-39)-NH₂,
H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(O)25, Asp28] Exedin-4(1-39)-NH₂,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(O)25, Asp28] Exedin-4(1-39)-NH₂,
des Pro36, Pro37, Pro38 [Trp(O)25, Asp28] Exedin-4(1-39)-(Lys)6-NH₂,
H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(O)25, Asp28] Exedin-4(1-39)-(Lys)6-NH₂,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(O)25, Asp28] Exedin-4(1-39)-(Lys)6-NH₂,
H-(Lys)6-des Pro36 [Met(O)14, Asp28] Exedin-4(1-39)-Lys6-NH₂,
des Met(O)14 Asp28 Pro36, Pro37, Pro38 Exedin-4(1-39)-NH₂,
H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exedin-4(1-39)-NH₂,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exedin-4(1-39)-NH₂,
des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exedin-4(1-39)-(Lys)6-NH₂,
H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exedin-4(1-39)-(Lys)6-NH₂,
H-Asn-(Glu)5 des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exedin-4(1-39)-(Lys)6-NH₂,
H-Lys6-des Pro36 [Met(O)14, Trp(O)25, Asp28] Exedin-4(1-39)-Lys6-NH₂,
H-des Asp28 Pro36, Pro37, Pro38 [Met(O)14, Trp(O)25] Exedin-4(1-39)-NH₂,
H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exedin-4(1-39)-NH₂,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O)25, Asp28] Exedin-4(1-39)-NH₂,
des Pro36, Pro37, Pro38 [Met(O)14, Trp(O)25, Asp28] Exedin-4(1-39)-(Lys)6-NH₂,
H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O)25, Asp28] Exedin-4(S1-39)-(Lys)6-NH₂,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O)25, Asp28] Exedin-4(1-39)-(Lys)6-NH₂;

or a pharmaceutically acceptable salt or solvate of any one of the afore-mentioned Exedin-4 derivative.

Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008, Chapter 50, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatotropine (Somatotropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin.

A polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof. An example of a pharmaceu-

tically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.

Pharmaceutically acceptable salts are for example acid addition salts and basic salts. Acid addition salts are e.g. HCl or HBr salts. Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na⁺, or K⁺, or Ca²⁺, or an ammonium ion N⁺(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group. Further examples of pharmaceutically acceptable salts are described in "Remington's Pharmaceutical Sciences" 17. ed. Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa., U.S.A., 1985 and in Encyclopedia of Pharmaceutical Technology.

Pharmaceutically acceptable solvates are for example hydrates.

The delay box may be employed with other types of auto-injectors.

The cap with the sheet metal spring may also be applied with other auto-injectors and injection devices.

Further scope of applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will become more fully understood from the detailed description given herein below and the accompanying drawings which are given by way of illustration only, and thus, are not limiting of the present invention, and wherein:

FIG. 1 are two longitudinal sections of an auto-injector with a single compression spring for advancing a syringe with a needle, injecting a dose of medicament and retracting the syringe and needle, the auto-injector as-delivered,

FIG. 2 are two longitudinal sections of the auto-injector with the syringe and needle advanced and the dose expelled from the syringe,

FIG. 3 is a perspective sectional view of the auto-injector in the initial state of FIG. 1,

FIG. 4 is another perspective sectional view of the auto-injector of FIG. 3, and

FIG. 5 is a detail view of the distal end of the auto-injector with a delay box,

FIG. 6 is a detailed view of the proximal end of the autoinjector showing the cap and needle shield remover.

Corresponding parts are marked with the same reference symbols in all figures.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

FIG. 1 shows two longitudinal sections in different section planes of an auto-injector 1, the different section planes approximately 90° rotated to each other. The auto-injector 1 comprises an elongate housing 2. A syringe 3, e.g. a Hypak syringe, with a hollow needle 4 is arranged in a proximal part of the auto-injector 1. When the auto-injector 1 or the syringe 3 is assembled a protective needle shield 5 is

attached to the needle 4. A stopper 6 is arranged for sealing the syringe 3 distally and for displacing a liquid medicament M through the hollow needle 4. The syringe 3 is held in a tubular syringe carrier 7 and supported at its proximal end therein. A single compression spring 8 is arranged in a distal part of the auto-injector 1. A plunger 9 is arranged for forwarding the spring force of the compression spring 8.

Inside the housing 2 a retraction sleeve 10 is slidably arranged. Before the injection is triggered as shown in FIG. 1 the retraction sleeve 10 is in a maximum proximal position and prevented from moving in distal direction D by means of stops 11 caught behind latches 12 in the housing 2. A distal end of the compression spring 8 bears against an end face 13 of the retraction sleeve 10. Due to the stops 11 and latches 12 the force of the compression spring 8 is thus reacted into the housing 2. The proximal end of the compression spring 8 bears against a decoupling member 14 arranged around the plunger 9. Distally from the end face 13 the retraction sleeve has two or more resilient arms 15 for holding a stud 16 and keeping it from being moved in proximal direction P. The stud 16 is arranged at the distal end of the plunger 9. The stud 16 and the resilient arms 15 have corresponding ramp features for pushing the resilient arms 15 apart in order to allow the stud 16 and the plunger 9 to move in proximal direction P.

The decoupling member 14 comprises a thrust face 17 for bearing against a proximal end of the compression spring 8. Proximally from the thrust face 17 two or more resilient decoupling arms 18 are provided at the decoupling member 14, the decoupling arms 18 having inner ramped surfaces bearing against a first shoulder 19 in the plunger 9 in proximal direction P. The resilient decoupling arms 18 are supported by an inner wall of the retraction sleeve 10 in this situation so they cannot flex outward and slip past the first shoulder 19.

A trigger button 20 is arranged at the distal end D of the auto-injector 1. The trigger button 20 may be pushed in proximal direction P in order to start an injection. As long as the trigger button 20 is not pushed the resilient arms 15 are caught between two or more retainers 21 arranged at the trigger button 20 so the resilient arms 15 cannot flex outward and the stud 16 although proximally biased by the compression spring 8 cannot slip through.

The syringe carrier 7 is engaged for joint axial movement with a syringe holder 22 which is slidably arranged in the retraction sleeve 10. The syringe holder 22 is provided with two or more resilient syringe holder arms 23 arranged distally. The syringe holder arms 23 have a respective inclined surface for bearing against a second shoulder 24 in the plunger 9 arranged proximally from the first shoulder 19. In the initial position shown in FIG. 1 the syringe holder arms 23 are supported by an inner surface of the housing 2 so they cannot flex outward and the second shoulder 24 cannot slip through. In order to support the syringe holder arms 23 at the housing 2 a respective number of apertures are provided in the retraction sleeve 10.

FIG. 1 shows the auto-injector 1 as-delivered with a cap 25 screwed onto to the proximal end P of the auto-injector 1. FIG. 6 shows details of the proximal end P with the cap 25. The cap 25 comprises a sheet metal clip 26 with two or more barbs 27 extending through an orifice into the proximal end P of the auto-injector 1. The sheet metal clip 26 is mounted to the cap 25 for joint axial movement with respect to a longitudinal axis of the auto-injector 1. However, the sheet metal clip 26 may rotate independently from the cap 25. This may be achieved by attaching the sheet metal clip 26 with a hole in its base onto a pin protruding inwardly

11

from the cap 25 and deforming the pin to form a mushroom-shaped closing head 28 so as to prevent the sheet metal clip 26 from being removed while allowing some clearance for the sheet metal clip 26 to rotate. When the cap 25 is screwed onto the proximal P end of the auto-injector 1 the barbs 27 are pushed down the protective needle shield 5 and snap into a circumferential notch arranged in the protective needle shield 5 or behind a shoulder thereof.

When a user wants to operate the auto-injector 1 the first step is to unscrew the cap 25. Thus the barbs 27 pull the protective needle shield 5 off the syringe 3 in proximal direction P and through the orifice making the syringe 3 ready to be used.

A safety button 29 is arranged laterally at the distal part of the housing 2. The safety button 29 serves for interlocking with the trigger button 20 in a manner to prevent the trigger button 20 from being inadvertently operated without the safety button 29 being released from a first blocking position.

Consequently, in order to operate the trigger button 20 the safety button 29 has to be pushed transversally with respect to the longitudinal axis against the force of a spring element 30 which is formed in the safety button 29. The safety button 29 is pivoted in the middle so pushing the proximal end of the safety button 29 inward pulls an interlock 31 at its proximal end obstructing the trigger button 20 outward so the trigger button 20 can be pushed.

When the trigger button 20 is pushed the retainers 21 are pushed in proximal direction P so the resilient arms 15 are allowed to flex outward. Under load of the compression spring 8 the inclined surfaces of the stud 16 force the resilient arms 15 apart until the stud 16 can slip through.

The second shoulder 24 pushes the syringe holder 22, syringe carrier 7 and syringe 3 forward while no load is exerted onto the stopper 6. The hollow needle 4 appears from the proximal end P and is inserted into an injection site, e.g. a patient's skin.

The forward movement continues until the syringe holder 22 bottoms out at a first abutment 32 in the housing 2 (see FIG. 2). The travel from the initial position (cf. FIG. 1) up to this point defines an injection depth, i.e. needle insertion depth.

When the syringe holder 22 has nearly bottomed out the resilient syringe holder arms 23 have reached a widened portion 2.1 of the housing 2 where they are no longer supported by the inner wall of the housing 2. However, since the force required to insert the needle 4 is relatively low the second shoulder 24 will continue to drive forward the syringe holder 22 until proximal travel is halted at the first abutment 32. At this point the syringe holder arms 23 are flexed out by the continued force of the second shoulder 24 and allow it to slip through. Now the plunger 9 no longer pushes against the syringe holder 22 but against the stopper 6 for expelling the medicament M from the syringe 3 and injecting it into or through the patient's skin.

When the stopper 6 has nearly bottomed out in the syringe 3 (cf. FIG. 2) the decoupling member 14 has reached a position where it pushes against the latches 12 in a manner to decouple the retraction sleeve 10 from the housing 2, so the retraction sleeve 10 may slide in distal direction D. Thus the compression spring 8 is no longer grounded with its distal end in the housing 2. Instead, as soon as the decoupling member 14 has bottomed out at a second abutment 33 the proximal end of the compression spring 8 gets grounded in the housing while the distal end is pulling the retraction sleeve 10 in distal direction D.

12

Just before the decoupling member 14 decouples the retraction sleeve 10 from the housing 2 the decoupling arms 18 reach an aperture 34 in the retraction sleeve 10 (see FIG. 4) so they are no longer kept from being flexed outward. The decoupling arms 18 are thus pushed outward by the first shoulder 19 pushing against its ramped surfaces so the first shoulder 19 slips through in distal direction as soon as the decoupling member 14 has hit the second abutment 33.

The syringe holder 22 is taken along in distal direction D by the retraction sleeve 10, e.g. by a front face 35. Thus the syringe 3 and needle 4 are retracted into a safe position inside the housing 2, e.g. into the initial position. The plunger 9, no longer bearing against the decoupling arms 18 is pulled back too.

In the distal part of the auto-injector 1 a delay box 36 is arranged (see FIG. 5 for details). The delay box 36 comprises a circumferential outer wall 37 with a back collar 38 attached to the housing 2 and a circumferential inner wall 39 with a front collar 40 attached to the retraction sleeve 10. A volume between the outer wall 37 and inner wall 39 is filled with a viscous fluid, such as silicon grease. As the retraction sleeve 10 is moved in distal direction D the inner wall 39 glides along the outer wall 37 wherein the back collar 38 and front collar 40 increasingly reduce the volume. One or more holes (not shown) provided in a part of the delay box 36 allow the viscous fluid to be pushed out as the volume decreases. The force required to do this slows down the motion of the retraction sleeve 10.

The retraction sleeve 10 is released by the decoupling member 14 from the housing 2 a certain amount of time or travel before the stopper 6 bottoms out in the syringe 3 and the distal motion of the retraction sleeve 10 begins. The motion of the retraction sleeve is slowed down by the delay box 36. Due to a gap 41 between the front face 35 and the syringe holder 22 the retraction sleeve 10 is not yet dragging the syringe back in distal direction D. The plunger 9 is still pushing against the stopper 6 and expelling residual medicament M. As the stopper 6 hits the proximal end of the syringe 3 the stopper 6 and plunger 9 stop while the retraction sleeve 10 is still slowly moving back in distal direction D. The apertures 34 now meet the decoupling arms 18 allowing them to flex out and the plunger 9 to come clear. The retraction sleeve 10 has now travelled back far enough to close the gap 41 so the syringe holder 22, syringe carrier 7, syringe 3, needle 4 and plunger 9 are dragged back in distal direction D.

The cap 25 and the delay box 36 are not restricted to be used with the auto-injector 1 shown in the embodiments. Instead the cap 25 may be combined with any kind of auto-injector with the needle hidden in the housing prior to an injection. The delay box may be combined with any kind of auto-injector for ensuring full delivery of the syringe's contents and reliable triggering of the retraction, irrespective of the spring means or driving means used in the respective auto-injector.

The housing 2 may have at least one viewing window for inspecting the syringe 3.

The auto-injector 1 may preferably be used for subcutaneous or intra-muscular injection, particularly for delivering one of an analgetic, an anticoagulant, insulin, an insulin derivate, heparin, Lovenox, a vaccine, a growth hormone, a peptide hormone, a proteine, antibodies and complex carbohydrates.

The aforementioned arrangement for coupling the plunger (9) to either, the syringe (3) or the stopper (6), may be applied in any auto-injector having a plunger for forwarding a force of a drive means to a syringe with a stopper. The

13

primary advantage of this arrangement ensures the load from the drive means is not transferred directly to the stopper until the needle is inserted in the patient, thus avoiding a wet injection. The arrangement comprises the syringe holder (22) and associated syringe holder arms (23), a shoulder (e.g. the second shoulder 24) on the plunger (9), the support of the holder arms (23) by an inner surface in order to prevent them from flexing out in a first position and, a widened portion (2.1) for allowing them to flex radially and to disconnect from the plunger when in a more proximal position. The spring means or other drive means, the ability to retract the syringe or to forward a needle shroud after injection and other features described herein are not required for the prevention of a wet injection.

LIST OF REFERENCES

1 auto-injector
 2 housing
 2.1 widened portion
 3 syringe
 4 hollow needle
 5 protective needle shield
 6 stopper
 7 syringe carrier
 8 spring means, compression spring
 8.1 distal end
 8.2 proximal end
 9 plunger
 10 retraction sleeve
 11 stop
 12 latch
 13 end face
 14 decoupling member
 15 resilient arm
 16 stud
 17 thrust face
 18 decoupling arm
 19 first shoulder
 20 activating means, trigger button
 21 retainer
 22 syringe holder
 23 syringe holder arm
 24 second shoulder
 25 cap
 26 sheet metal clip
 27 barb
 28 closing head
 29 safety button
 30 spring element
 31 interlock
 32 first abutment
 33 second abutment
 34 aperture
 35 front face
 36 delay box
 37 outer wall
 38 back collar
 39 inner wall
 40 front collar
 41 gap
 D distal end, distal direction
 M medicament
 P proximal end, proximal direction

14

The invention claimed is:

1. An auto-injector comprising:

- a housing defining a longitudinal axis extending from a proximal end of the housing to a distal end of the housing, the proximal end of the housing configured to directly contact an injection site, and at least a portion of the housing being cylindrical;
- a plunger rod comprising an outer protrusion;
- a syringe holder configured to retain a syringe containing a medicament, the auto-injector being configured such that the syringe holder remains in one position relative to the housing by an engagement between the syringe holder and the plunger rod as a needle shield is removed from a proximal end of the syringe;
- a compression drive spring disposed around a distal portion of the plunger rod and biasing the plunger rod via the outer protrusion of the plunger rod in a proximal direction relative to the housing;
- a cap configured to be releasably attached to the proximal end of the housing to cover an opening at the proximal end of the housing, the auto-injector being configured such that the syringe holder engages the plunger rod to limit proximal movement of the syringe holder relative to the plunger rod when the cap is attached to the proximal end of the housing, the cap being configured such that removal of the cap from the proximal end of the housing removes the needle shield from the proximal end of the syringe;
- a button disposed at the distal end of the housing;
- a safety member disposed at a distal portion of the housing, the safety member configured to (i) limit a proximal movement of the button relative to the housing when the safety member is in a first position relative to the housing, and (ii) allow the proximal movement of the button relative to the housing when the safety member is in a second position relative to the housing, the auto-injector being configured such that after a user moves the safety member from the first position to the second position the user can move the button proximally relative to the housing; and
- a collar attached to the housing, the collar containing a viscous substance for delaying retraction of a needle of the syringe into the housing,

wherein the housing comprises at least one window for viewing the syringe when the syringe is retained by the syringe holder.

2. The auto-injector of claim 1, comprising a decoupling member configured to release a resilient arm from being engaged to a first protrusion, the collar configured to delay retraction of the needle after the resilient arm has been released from being engaged to the first protrusion.

3. The auto-injector of claim 2, wherein the decoupling member and the plunger rod are separate components of the auto-injector.

4. The auto-injector of claim 2, wherein the compression drive spring is located on a distal side of the decoupling member.

5. The auto-injector of claim 2, wherein the compression drive spring is configured to bias the plunger rod and the decoupling member proximally relative to the housing.

6. The auto-injector of claim 2, comprising a sleeve disposed in the housing, a distal end of the sleeve defining a distal opening for the plunger rod, an axially-extending sidewall of the sleeve defining a longitudinal opening for the decoupling member, and the sleeve being a monolithic structure.

15

7. The auto-injector of claim 6, wherein the distal opening is located concentrically about the longitudinal axis of the housing, and the longitudinal opening is proximal to the distal opening.

8. The auto-injector of claim 1, wherein the button comprises a proximally-extending portion configured to allow the plunger rod to be released from being held in a distal plunger position within the housing.

9. The auto-injector of claim 1, wherein the auto-injector is configured such that the syringe holder remains in the one position by the engagement between the syringe holder and the plunger rod when the cap is attached to the proximal end of the housing.

10. The auto-injector of claim 1, comprising a sleeve disposed in the housing, the sleeve configured to move in a distal direction relative to the housing during needle retraction.

11. An auto-injector comprising:

a housing defining a longitudinal axis extending from a proximal end of the housing to a distal end of the housing, the proximal end of the housing configured to directly contact an injection site, and at least a portion of the housing being cylindrical;

a plunger rod comprising an outer protrusion;

a syringe holder configured to retain a syringe containing a medicament, the auto-injector being configured such that the syringe holder remains in one position relative to the housing by an engagement between the syringe holder and the plunger rod as a needle shield is removed from a proximal end of the syringe;

a compression drive spring disposed around a distal portion of the plunger rod and biasing the plunger rod via the outer protrusion of the plunger rod in a proximal direction relative to the housing;

a sleeve disposed in the housing; and

a cap configured to be releasably attached to the proximal end of the housing to cover an opening at the proximal end of the housing, the auto-injector being configured such that the syringe holder engages the plunger rod to limit proximal movement of the syringe holder relative to the plunger rod when the cap is attached to the proximal end of the housing, the cap being configured such that removal of the cap from the proximal end of the housing removes the needle shield from the proximal end of the syringe;

a collar attached to the housing, the collar containing a viscous substance for delaying retraction of a needle into the housing,

wherein the housing comprises at least one viewing window for viewing the syringe when the syringe is retained by the syringe holder.

12. The auto-injector of claim 11, comprising a button comprising a proximally-extending portion configured to allow the plunger rod to be released from being held in a distal position within the housing.

13. The auto-injector of claim 12, comprising a safety member disposed at a distal portion of the housing, the safety member configured to (i) limit a proximal movement of the button relative to the housing when the safety member is in a first position relative the housing, and (ii) allow the proximal movement of the button relative to the housing when the safety member is in a second position relative the housing.

14. The auto-injector of claim 11, wherein a proximal-facing surface of the sleeve that is inside the sleeve is engaged to a distal end the compression drive spring, and a proximal end of the compression drive spring is coupled to

16

the plunger rod via the outer protrusion of the plunger rod such that the plunger rod is proximally biased relative to the sleeve.

15. The auto-injector of claim 11, wherein the auto-injector is configured such that needle retraction does not begin until after a resilient arm has been released from being engaged to a first protrusion of the sleeve.

16. The auto-injector of claim 15, wherein the auto-injector is configured such that the needle retraction does not begin until after the viscous substance has retarded a relative movement within the auto-injector.

17. The auto-injector of claim 15, comprising a decoupling member configured to release the resilient arm from being engaged to the first protrusion.

18. The auto-injector of claim 17, wherein the decoupling member and the plunger rod are separate components of the auto-injector.

19. An auto-injector comprising:

a housing defining a longitudinal axis extending from a proximal end of the housing to a distal end of the housing, the proximal end of the housing configured to directly contact an injection site, and at least a portion of the housing being cylindrical;

a plunger rod comprising an outer protrusion;

a syringe holder configured to retain a syringe containing a medicament, the auto-injector being configured such that the syringe holder remains in a first position relative to the housing by an engagement between the syringe holder and the plunger rod as a needle shield is removed from a proximal end of the syringe;

a compression drive spring disposed around a distal portion of the plunger rod and biasing the plunger rod via the outer protrusion of the plunger rod in a proximal direction relative to the housing;

a sleeve disposed in the housing, and

a collar attached to the housing, the collar containing a viscous substance for delaying needle retraction, wherein the housing comprises at least one viewing window for viewing the syringe when the syringe is retained by the syringe holder.

20. The auto-injector of claim 19, wherein the syringe holder is configured to (i) slide within the sleeve during needle insertion, and (ii) be slidably coupled to the sleeve during needle retraction.

21. The auto-injector of claim 19, wherein the auto-injector is configured such that the sleeve does not axially move relative to the housing until after the viscous substance has retarded a relative movement within the auto-injector.

22. The auto-injector of claim 19, wherein the auto-injector is configured such that the sleeve does not axially move relative to the housing until after a resilient arm has been released from being engaged to a first protrusion of the sleeve.

23. The auto-injector of claim 22, wherein a distal end of the sleeve defines a distal opening located concentrically about the longitudinal axis of the housing, and an axially-extending sidewall of the sleeve defines a longitudinal opening.

24. The auto-injector of claim 23, wherein the sleeve is a monolithic structure.

25. The auto-injector of claim 23, wherein the longitudinal opening is sized to allow a decoupling member to extend through the longitudinal opening for allowing a proximal-facing surface of the decoupling member to engage a distally-facing surface of the resilient arm to release the resilient arm from being engaged to the first protrusion.

17

26. The auto-injector of claim 25, wherein the decoupling member and the plunger rod are distinct components of the auto-injector.

27. The auto-injector of claim 19, comprising a cap configured to be releasably attached to a proximal end of the housing to cover an opening at the proximal end of the housing, the auto-injector being configured such that the syringe holder engages the plunger rod to limit proximal movement of the syringe holder relative to the plunger rod when the cap is attached to the proximal end of the housing.

28. An auto-injector comprising:

a housing defining a longitudinal axis extending from a proximal end of the housing to a distal end of the housing, the proximal end of the housing configured to directly contact an injection site;

a syringe holder configured to retain a syringe containing a medicament, the auto-injector being configured such that the syringe holder remains in a first position relative to the housing as a needle shield is removed from a proximal end of the syringe; and

18

a collar attached to the housing, the collar containing a viscous substance for delaying needle retraction, wherein the housing comprises at least one viewing window for viewing the syringe when the syringe is retained by the syringe holder.

29. The auto-injector of claim 28, comprising a sleeve configured to releasably hold a plunger rod of the auto-injector in a distal plunger position within the housing against a biasing force of a compression drive spring.

30. The auto-injector of claim 29, comprising a cap configured to be releasably attached to the proximal end of the housing to cover the proximal end of the housing, the cap being configured such that removal of the cap from the proximal end of the housing removes the needle shield from the proximal end of the syringe, and the auto-injector is configured such that the syringe holder engages the plunger rod to limit proximal movement of the syringe holder relative to the plunger rod when the cap is attached to the proximal end of the housing.

* * * * *